- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01074554
Trial of Antimycobacterial Therapy in Sarcoidosis (CLEAR)
Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as defined by the clinical presentation consistent with sarcoidosis, biopsy finding granulomas, and no alternative for the cause of the granulomas, such as tuberculosis
- Patients must have chronic cutaneous skin lesions with or without taking chronic therapy (corticosteroids, methotrexate (max 10mg/week), azathioprine, hydroxychloroquine, cyclophosphamide, minocycline, doxycycline and chloroquine), in which the dose has not been altered in the 2 months prior to starting the study.
Subject has a diagnosis of cutaneous sarcoidosis for greater than 6 months with a Sarcoidosis Activity and Severity Index assessment score of at least 4. Diagnosis can be made by either:
- Skin lesions characteristic of sarcoidosis and a biopsy showing granulomas with no evidence of mycobacteria, fungus, or malignancy.
- A biopsy that does not show granulomas, but the patient has characteristic skin lesions and history of clinical features suggesting sarcoidosis (previous biopsy revealing noncaseating granuloma, bilateral hilar adenopathy, erythema nodosum, uveitis, raised ACE level, BAL lymphocytosis (CD4:CD8>3.5), panda/lambda sign on gallium scan)
Accepted clinical variants include, but are not necessarily limited to the following:
- lupus pernio
- nodular
- subcutaneous
- annular
- angiolupoid
- plaque
- papular
- lichenoid
- psoriasiform
For purposes of this study "moderate to severe cutaneous sarcoidosis" is defined as the presence of sarcoidal skin lesions with any of the following features:
- At least 5 easily visible facial lesions, or
- Disease which involves > 3% BSA, or
- Disease which confers functional impairment (e.g. nasal or visual field obstruction), or
- Disease which confers significant symptoms of itching and/or pain.
If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or is using one of the following methods of birth control for the duration of the study and 90 days after study completion:
- condoms, sponge, foams, jellies, diaphragm, or intrauterine device
- contraceptives (oral or parenteral) for three months prior to study drug administration
- a vasectomized sole partner
- Females of childbearing potential must have a negative serum pregnancy test at screening visit.
Exclusion Criteria:
- No consent/inability to obtain consent.
- Age less than 18 years of age.
- Inability to obtain biopsy or draw blood.
- CPK, ALT or AST >5 times upper limit of normal (ULN)
- Pregnancy or breast feeding.
- Current use of medications metabolized by rifampin (See Appendix).
- Allergy to macrolides, quinolones or rifamycins.
- Visual Impairment as defined by differentiating colors.
- Family or personal history of long QT syndromes.
- Patients receiving another interventional investigational drug within the 30 days prior to dosing
- Use of any investigational medication within the past 28 days prior to study enrollment.
- Subject has been hospitalized for infection or received IV antibiotics within the previous 2 months prior to baseline.
- Subject has a history of tuberculosis at anytime or close contact with a person with active tuberculosis within the previous 6 months, or persistent or active infections requiring hospitalization or treatment with IV antibiotics, IV antiretrovirals, or IV antifungals within 30 days of baseline, OR oral antibiotics, antivirals, or antifungals for purpose of treating infection, within 14 days of baseline.
- Evidence of other active skin diseases or skin infections during screening that may interfere with evaluation of sarcoidosis.
- Subject has an active infection requiring systemic antibiotics at time of screening
- Subject has a history of listeriosis, treated or untreated tuberculosis, exposure to individuals with tuberculosis.
Subject has a variant of sarcoidosis that is not amenable to study evaluation, in the absence of chronic indurated lesions, such as:
- Acute, "benign" sarcoid associated with erythema nodosum
- Acute iritis
- Ichthyosiform sarcoidosis
- Hypo- or hyperpigmented macular sarcoidosis
- Ulcerative sarcoidosis
- Erythroderma
- Alopecia
- Patients otherwise unsuitable for participation in the opinion of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Antibiotic Regimen
The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD. All four drugs are given concomitantly. |
Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
Other Names:
|
Placebo Comparator: Placebo Regimen
The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills
|
lactose control tablets; one for each antibiotic with equivalent pills
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions
Time Frame: Baseline to 8 weeks
|
Baseline to 8 weeks
|
|
Granuloma Burden
Time Frame: Baseline to 8 weeks
|
Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy)
|
Baseline to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy.
Time Frame: Baseline to 8 weeks
|
Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation.
The modification was that the same scale was applied to any part of the body, instead of the face alone.
The scale range is 0 (no problem) to 72 (very severe).
|
Baseline to 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wonder P Drake, MD, Vanerbilt University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Sarcoidosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Leprostatic Agents
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Cytochrome P-450 CYP1A2 Inhibitors
- Anti-Infective Agents, Urinary
- Renal Agents
- Anti-Bacterial Agents
- Rifampin
- Azithromycin
- Levofloxacin
- Ethambutol
Other Study ID Numbers
- 091103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoidosis
-
Celularity IncorporatedTerminatedStage 2 Pulmonary Sarcoidosis | Stage 3 Pulmonary SarcoidosisUnited States
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedSarcoidosis; Antimycobacterial TherapyUnited States
-
University Hospital, LilleTerminated
-
Alexandria UniversityCompletedEndobronchial Mucosal Pathology in Pulmonary SarcoidosisEgypt
-
Heart Center Leipzig - University HospitalRecruiting
-
British Columbia Cancer AgencyApproved for marketing
-
University of EdinburghUnknown
-
Mayo ClinicCompleted
-
Pusan National University Yangsan HospitalCompletedMuscular SarcoidosisKorea, Republic of
-
Ottawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR); Ontario Ministry of Health and...Recruiting
Clinical Trials on Antibiotic Regimen
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Physicians' Services Incorporated Foundation and other collaboratorsCompletedBone Neoplasms | InfectionUnited States, Canada, Netherlands, Australia, Spain, Singapore, Brazil, India, Argentina, Austria, South Africa, Egypt
-
Instituto do CoracaoFundação de Amparo à Pesquisa do Estado de São PauloCompletedSepsis | Fungemia | BacteremiaBrazil
-
Fundación Pública Andaluza para la gestión de la...Spanish Clinical Research Network - SCReN; Spanish Network for Research in...RecruitingEnterococcal BacteremiaSpain
-
Fundación Pública Andaluza para la gestión de la...Spanish Clinical Research Network - SCReN; CIBER (Infectious diseases)Recruiting
-
Medical University of South CarolinaTerminatedHematological MalignanciesUnited States
-
Pearl Therapeutics, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
GlaxoSmithKlineCompleted
-
University of BedfordshireUnknownCardiovascular Diseases | Diabetes | Sedentary Lifestyle | Type 2 Diabetes | Sedentary Behavior | Cardiovascular Risk FactorUnited Kingdom
-
Florida State UniversityAlliance for Potato Research and EducationCompletedOverweight and Obesity | Type2 Diabetes | Arterial Stiffness | Cardiometabolic SyndromeUnited States
-
Novartis PharmaceuticalsActive, not recruitingStudy of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis (ONWARDS)OsteoarthritisTaiwan, Spain, United Kingdom, United States, Argentina, Australia, Denmark, India, China, Czechia, Canada, Japan, Poland, Mexico, Estonia